Guggenheim Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target boosted by equities research analysts at Guggenheim from $87.00 to $90.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective suggests a potential upside of 18.62% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. The Goldman Sachs Group restated a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Mizuho started coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price on the stock. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.00.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $75.87 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 4.25. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of -46.83, a PEG ratio of 1.05 and a beta of 0.57. The company’s 50-day moving average is $72.12 and its two-hundred day moving average is $68.43. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the sale, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 8.97% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TARS. State of Wisconsin Investment Board increased its holdings in Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after purchasing an additional 332 shares during the period. Federated Hermes Inc. grew its position in shares of Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after buying an additional 339 shares in the last quarter. Valeo Financial Advisors LLC grew its position in shares of Tarsus Pharmaceuticals by 11.1% during the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after buying an additional 392 shares in the last quarter. Creative Planning increased its stake in shares of Tarsus Pharmaceuticals by 3.3% during the third quarter. Creative Planning now owns 12,367 shares of the company’s stock worth $735,000 after buying an additional 393 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Tarsus Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock valued at $169,000 after acquiring an additional 431 shares in the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target materially and reiterated a positive stance (Outperform), which supports upside expectations for the shares. Oppenheimer Raises PT
• Positive Sentiment: Guggenheim raised its price target on TARS to $90 and maintained a Buy rating, providing additional analyst-level backing for further gains. Guggenheim PT $90
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences—this increases management access to investors and can help sustain the re-rating momentum if management delivers encouraging updates. Investor Conferences
• Neutral Sentiment: A market commentary questioned whether Tarsus has been re-rated too cautiously following XDEMVY adoption headlines; this article frames debate about valuation vs execution but does not add hard fundamentals. Market Rerate Analysis
• Negative Sentiment: HC Wainwright trimmed multiple near-term and multi-year EPS forecasts in its Feb. 24 research note — lowering Q1 2026 to about ($0.42) (from $0.05), Q2 to ~($0.17) (from $0.09), Q3 to ~($0.07) (from $0.18), and cutting Q4/QFY and FY2027–FY2029 targets (e.g., FY2027 to $2.33 from $2.90, FY2028 to $3.10 from $4.26, FY2029 to $4.68 from $5.87). These downward revisions increase short-term earnings uncertainty and weigh on fundamental expectations.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.